RYTM News and Press, Rhythm Pharmaceuticals Inc. From 12/11/20

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the appointments of Camille L. Bedrosian, M.D., and Lynn...

Gainers: SCWorx (WORX) +80%.FreightCar America (RAIL) +48%.ReneSola (SOL) +44%.Oramed Pharmaceuticals (ORMP) +40%.Apex Technology Acquisition (APXT) +30%.Kaleyra (KLR) +29%.Rhythm Pharmaceuticals (RYTM) +27%.Aurora Mobile (JG) +27%.Novavax (NVAX) +20%.Arcturus Therapeutics (ARC...

Gainers: SCWorx (WORX) +90%, Oramed Pharmaceuticals (ORMP) +31%, Rhythm Pharmaceuticals (RYTM) +19%, Genfit (GNFT) +15%, Verastem (VSTM) +13%.Losers: AnPac Bio-Medical Science (ANPC) -11%, Sientra (SIEN) -9%, Alphatec Holdings (ATEC)...

SCWorx (WORX) +100%.Professional Diversity Network (IPDN) +25%.Apex Technology Acquisition (APXT) +20%.Genfit SA (GNFT) +18%.Xinyuan Real Estate (XIN) +17% on Q3 results.Rhythm Pharmaceuticals (RYTM) +16% as FDA OKs it's Imcivree for weight management in obese patients.Shi...

The FDA has approved Rhythm Pharmaceuticals' (RYTM) Imcivree (setmelanotide) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin ((POMC)), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor ((LEPR...

-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval supports company’s approach to address rare gen...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...

-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from long-term extension study in POMC deficiency obesity ...